Insmed Future Growth

Future criteria checks 2/6

Insmed is forecast to grow earnings and revenue by 53.7% and 46% per annum respectively. EPS is expected to grow by 53.7% per annum. Return on equity is forecast to be -175% in 3 years.

Key information

53.7%

Earnings growth rate

53.7%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	46.0%
Future return on equity	-175.0%
Analyst coverage	Good
Last updated	29 Aug 2024

Recent future growth updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Recent updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

Dec 18

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Jul 28

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jul 01

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Apr 18

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Feb 23

Insmed inks financing agreements to raise $500M

Oct 19

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24

Earnings and Revenue Growth Forecasts

NasdaqGS:INSM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,022	-435	-270	N/A	14
12/31/2025	537	-739	-663	-628	16
12/31/2024	357	-842	-924	-618	15
6/30/2024	329	-803	-591	-574	N/A
3/31/2024	315	-747	-589	-574	N/A
12/31/2023	305	-750	-550	-536	N/A
9/30/2023	281	-724	-524	-509	N/A
6/30/2023	269	-696	-476	-462	N/A
3/31/2023	257	-547	-453	-442	N/A
12/31/2022	245	-482	-410	-400	N/A
9/30/2022	242	-434	-388	-381	N/A
6/30/2022	221	-416	-374	-367	N/A
3/31/2022	201	-438	-348	-340	N/A
12/31/2021	188	-435	-371	-363	N/A
9/30/2021	174	-424	-354	-346	N/A
6/30/2021	171	-375	-336	-329	N/A
3/31/2021	168	-319	-295	-290	N/A
12/31/2020	164	-294	-226	-219	N/A
9/30/2020	169	-245	-215	-197	N/A
6/30/2020	164	-242	-223	-191	N/A
3/31/2020	151	-247	-276	-235	N/A
12/31/2019	136	-254	-293	-251	N/A
9/30/2019	101	-293	-310	-276	N/A
6/30/2019	62	-320	-311	-290	N/A
3/31/2019	32	-330	-278	-264	N/A
12/31/2018	10	-324	-273	-258	N/A
9/30/2018	N/A	-298	-248	-236	N/A
6/30/2018	N/A	-256	-219	-209	N/A
3/31/2018	N/A	-224	N/A	-190	N/A
12/31/2017	N/A	-193	N/A	-160	N/A
9/30/2017	N/A	-196	N/A	-169	N/A
6/30/2017	N/A	-188	N/A	-162	N/A
3/31/2017	N/A	-180	N/A	-154	N/A
12/31/2016	N/A	-176	N/A	-147	N/A
9/30/2016	N/A	-139	N/A	-116	N/A
6/30/2016	N/A	-132	N/A	-109	N/A
3/31/2016	N/A	-124	N/A	-105	N/A
12/31/2015	N/A	-118	N/A	-101	N/A
9/30/2015	N/A	-105	N/A	-86	N/A
6/30/2015	N/A	-98	N/A	-83	N/A
3/31/2015	N/A	-92	N/A	-77	N/A
12/31/2014	N/A	-79	N/A	-64	N/A
9/30/2014	N/A	-78	N/A	-66	N/A
6/30/2014	N/A	-71	N/A	-61	N/A
3/31/2014	N/A	-57	N/A	-48	N/A
12/31/2013	N/A	-56	N/A	-47	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INSM's revenue (46% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: INSM's revenue (46% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INSM is forecast to be unprofitable in 3 years.

Insmed Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 11%, revenue upgraded

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Price target increased by 8.7% to US$82.63

Price target increased by 7.0% to US$73.44

Price target increased by 25% to US$56.56

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Recent updates

Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up

Chief Medical Officer notifies of intention to sell stock

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Chief People Strategy Officer recently sold US$686k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Insider notifies of intention to sell stock

Is Insmed (NASDAQ:INSM) A Risky Investment?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 8.7% to US$82.63

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Price target increased by 7.0% to US$73.44

Chief Medical Officer exercised options and sold US$768k worth of stock

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Chief Financial Officer notifies of intention to sell stock

Price target increased by 25% to US$56.56

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

Insmed Incorporated Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

New major risk - Share price stability

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

President recently sold US$566k worth of stock

President notifies of intention to sell stock

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed inks financing agreements to raise $500M

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022